A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs

Clinical Cancer Research

Volumn 21, Issue 14, 2015, Pages 3298-3306

  Yu, Shang Fan ^a   Zheng, Bing ^a   Go, Maryann ^a   Lau, Jeff ^a   Spencer, Susan ^a   Raab, Helga ^a   Soriano, Robert ^a   Jhunjhunwala, Suchit ^a   Cohen, Robert ^a   Caruso, Michele ^b   Polakis, Paul ^a   Flygare, John ^a   Polson, Andrew G ^a  

^a GENENTECH INC   (United States)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; NMS 249; PINATUZUMAB VEDOTIN; POLATUZUMAB VEDOTIN; SOBLIDOTIN; UNCLASSIFIED DRUG; 3'-DEAMINO-3'',4'-ANHYDRO-(2''-METHOXY-3''-OXY-4''-MORPHOLINYL)DOXORUBICIN; AMINOBENZOIC ACID DERIVATIVE; ANTIBODY CONJUGATE; AURISTATIN; CD22 ANTIGEN; DOXORUBICIN; OLIGOPEPTIDE;

ABCB1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HUMAN; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LYMPHOMA, NON-HODGKIN; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE;

AMINOBENZOATES; ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; MICE; MICE, INBRED ICR; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGOPEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; SIALIC ACID BINDING IG-LIKE LECTIN 2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942905381     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2035     Document Type: Article

References (15)

1. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44.
2. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.
3. Chu YW, Polson A. Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. Future Oncol 2013;9:355-68.
4. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405.
5. Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 2013;12:1255-65.
6. Palanca-Wessels MC, Flinn IW, Sehn LH, Patel M, Sangha R, Czuczman MS, et al. A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts 2012;120:56.
7. Advani R, Lebovic D, Brunvand M, Chen AI, Goy A, Chang JE, et al. A phase I study of DCDT2980S, an Antibody-Drug Conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts 2012;120:59.
8. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-82.
9. Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, et al. A doseescalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014;20:213-20.
10. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 2009;114:2721-9.
11. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32.
12. Sessa C, Valota O, Geroni C. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc Toxicol 2007;7:75-9.
13. Quintieri L, Geroni C, Fantin M, Battaglia R, Rosato A, Speed W, et al. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes. Clin Cancer Res 2005;11:1608-17.
14. Rund D. Multidrug resistance in lymphoma: is it time for clinical trials? Leuk Lymphoma 2007;48:643-4.
15. Sandor V, Wilson W, Fojo T, Bates SE. The role of MDR-1 in refractory lymphoma. Leuk Lymphoma 1997;28:23-31.